Detalhe da pesquisa
1.
In Vitro Activity of Ceftibuten-Avibactam against ß-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program.
Antimicrob Agents Chemother
; 67(1): e0134622, 2023 01 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36602322
2.
Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019.
Antimicrob Agents Chemother
; 67(5): e0140622, 2023 05 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37074173
3.
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 µg/mL), a Novel ß-Lactam/ß-Lactamase Inhibitor Combination.
J Clin Microbiol
; 61(7): e0165722, 2023 07 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37395644
4.
The primary pharmacology of ceftazidime/avibactam: resistance in vitro.
J Antimicrob Chemother
; 78(3): 569-585, 2023 03 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36702744
5.
Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
J Antimicrob Chemother
; 78(7): 1606-1615, 2023 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37161662
6.
The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.
J Antimicrob Chemother
; 78(4): 871-892, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36883356
7.
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by ß-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
J Antimicrob Chemother
; 78(11): 2672-2682, 2023 11 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37700689
8.
Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other ß-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
Antimicrob Agents Chemother
; 66(3): e0198521, 2022 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35225651
9.
The primary pharmacology of ceftazidime/avibactam: in vitro translational biology.
J Antimicrob Chemother
; 77(9): 2321-2340, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-35665807
10.
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
J Antimicrob Chemother
; 77(9): 2341-2352, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-35660869
11.
Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012-2018.
Ann Clin Microbiol Antimicrob
; 21(1): 13, 2022 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35313912
12.
Sex differences in gene expression in response to ischemia in the human left ventricular myocardium.
Hum Mol Genet
; 28(10): 1682-1693, 2019 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30649309
13.
Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.
Antimicrob Agents Chemother
; 65(7): e0200020, 2021 06 17.
Artigo
Inglês
| MEDLINE | ID: mdl-33972241
14.
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artigo
Inglês
| MEDLINE | ID: mdl-32071051
15.
In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017.
J Antimicrob Chemother
; 75(7): 1859-1873, 2020 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32277820
16.
In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17).
J Antimicrob Chemother
; 75(2): 384-391, 2020 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31742604
17.
Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.
J Antimicrob Chemother
; 75(5): 1165-1173, 2020 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32040168
18.
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ann Clin Microbiol Antimicrob
; 19(1): 14, 2020 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32238155
19.
The Public's Perception of the Severity and Global Impact at the Start of the SARS-CoV-2 Pandemic: A Crowdsourcing-Based Cross-Sectional Analysis.
J Med Internet Res
; 22(11): e19768, 2020 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33108314
20.
Erratum for Estabrook et al., "Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019".
Antimicrob Agents Chemother
; 68(3): e0164023, 2024 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38349140